Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics, Inc (RNTX)
:RNTX
Dry powder inhaler, Lti-03
Idiopathic Pulmonary Fibrosis (Ipf)
Phase II
Active Not Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Apr 28, 2025
―
Lti-03
Idiopathic Pulmonary Fibrosis
Phase I
Completed
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
May 20, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Rein Therapeutics, Inc (RNTX) have in its pipeline
RNTX is currently developing the following drugs: Dry powder inhaler, Lti-03, Lti-03. These drug candidates are in various stages of clinical development as the company works toward FDA approval.